Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ince

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Virology|February 13, 2009
Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalizationWilliam L Ince, Patrick R Harrington, Gretja L Schnell, et al.
Scientific Reports|June 14, 2019
Caveolin1 interacts with the glucocorticoid receptor in the lung but is dispensable for its anti-inflammatory actions in lung inflammation and Trichuris Muris infectionG Caratti, T Poolman, R J Hurst, et al.
Cell Host & Microbe|March 19, 2013
Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selectionSuman R Das, Scott E Hensley, William L Ince, et al.
Journal of the National Cancer Institute|July 7, 2005
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumabWilliam L Ince, Adrian M Jubb, Scott N Holden, et al.
Plos Pathogens|June 20, 2014
Biogenesis of influenza a virus hemagglutinin cross-protective stem epitopesJavier G Magadán, Meghan O Altman, William L Ince, et al.
Mbio|August 6, 2015
A Simple Flow-Cytometric Method Measuring B Cell Surface Immunoglobulin Avidity Enables Characterization of Affinity Maturation to Influenza A VirusGregory M Frank, Davide Angeletti, William L Ince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibDavid A Eberhard, Bruce E Johnson, Lukas C Amler, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Virology|February 13, 2009
Major coexisting human immunodeficiency virus type 1 env gene subpopulations in the peripheral blood are produced by cells with similar turnover rates and show little evidence of genetic compartmentalizationWilliam L Ince, Patrick R Harrington, Gretja L Schnell, et al.
Scientific Reports|June 14, 2019
Caveolin1 interacts with the glucocorticoid receptor in the lung but is dispensable for its anti-inflammatory actions in lung inflammation and Trichuris Muris infectionG Caratti, T Poolman, R J Hurst, et al.
Cell Host & Microbe|March 19, 2013
Defining influenza A virus hemagglutinin antigenic drift by sequential monoclonal antibody selectionSuman R Das, Scott E Hensley, William L Ince, et al.
Journal of the National Cancer Institute|July 7, 2005
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumabWilliam L Ince, Adrian M Jubb, Scott N Holden, et al.
Plos Pathogens|June 20, 2014
Biogenesis of influenza a virus hemagglutinin cross-protective stem epitopesJavier G Magadán, Meghan O Altman, William L Ince, et al.
Mbio|August 6, 2015
A Simple Flow-Cytometric Method Measuring B Cell Surface Immunoglobulin Avidity Enables Characterization of Affinity Maturation to Influenza A VirusGregory M Frank, Davide Angeletti, William L Ince, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinibDavid A Eberhard, Bruce E Johnson, Lukas C Amler, et al.
Pageof 3